此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

植入 CI622D 地塞米松洗脱人工耳蜗的成人与植入标准人工耳蜗 (CI622) 的成人的表现和听力相关结果 (DETECT)

2026年10月5日 更新者:Cochlear

一项关键、前瞻性、多中心、随机对照、盲法研究,评估地塞米松洗脱细长直电极 (CI622D) 与标准细长直电极 (CI622) 相比,在新植入的成人人群中降低阻抗的功效语言后、双侧、中重度至极重度感音神经性听力损失。

This clinical study will test a newly developed cochlear implant known as CI622D. This experimental cochlear implant has been designed to slowly release a drug called dexamethasone. Dexamethasone works to ease inflammation, which is common after any surgical procedure. The goal is to learn if there are added benefits in implant performance and hearing outcomes with the dexamethasone-releasing cochlear implant (CI622D) vs. the standard cochlear implant (CI622) without dexamethasone. The study will be conducted in adults with sensorineural hearing loss, a type of hearing loss caused by damage to the inner ear or auditory nerve. The study participants will undergo a series of tests that include testing their implant and their hearing. They will also complete questionnaires to see how they rate their hearing ability and their overall general health.

研究概览

研究类型

介入性

注册 (实际的)

50

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Freiburg Im Breisgau
      • Freiburg im Breisgau、Freiburg Im Breisgau、德国
        • Universitätsklinikum Freiburg
    • Lower Saxony
      • Hanover、Lower Saxony、德国
        • Medizinische Hochschule Hannover
      • Lille、法国
        • Centre Hospitalier Universitaire de Lille
      • Paris、法国
        • Hôpital Universitaire Pitié-Salpêtrière
      • Toulouse、法国
        • Centre Hospitalier Universitaire Toulouse
    • New South Wales
      • Sydney、New South Wales、澳大利亚
        • Westmead Private Hospital
      • Sydney、New South Wales、澳大利亚
        • Royal Prince Alfred Hospital
      • Sydney、New South Wales、澳大利亚
        • Macquarie University
    • Victoria
      • Melbourne、Victoria、澳大利亚
        • St Vincent Private Hospital
      • Melbourne E.、Victoria、澳大利亚
        • Royal Victorian Eye and Ear Hospital
      • Manchester、英国
        • Manchester Royal Infirmary

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Aged 18 years or older (at time of consent)
  • Clinically established post-linguistic bilateral moderately severe to profound sensorineural hearing loss
  • Meets local candidacy criteria for cochlear implantation
  • Compromised functional hearing with a hearing aid in the ear to be implanted
  • Willing to participate in and comply with all requirements of the protocol, including willingness to be randomised to either arm
  • Evidence of pneumococcal vaccination (e.g., Pneumovax) according to local guidelines prior to randomisation
  • Candidate is proficient in the language used to assess speech perception performance
  • Willing and able to provide written informed consent.

Exclusion Criteria:

  • Planned for a partial insertion of the electrode array
  • Intra-axial (within the brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted
  • Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment
  • Active autoimmune disease or active immunosuppressive therapy
  • Any of the following in the ear to be implanted within 3 months prior to enrolment: history of prior otologic surgery including grommets, or tympanic membrane perforation
  • Previously reported diagnosis of auditory neuropathy, in the ear to be implanted
  • Previously reported diagnosis, in the ear to be implanted, of Large Vestibular Aqueduct Syndrome (LVAS), Meniere's disease, or cochlear hydrops
  • Ossification, otosclerosis, malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, as confirmed by imaging, in the ear to be implanted
  • Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, temporo- parietal skull fracture or CSF leaks
  • History of bacterial meningitis
  • Known allergic reaction or contraindication to dexamethasone or corticosteroids
  • Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the subject
  • Severe, or poorer, sensorineural hearing loss of more than 20 years, as reported by the subject, in the ear to be implanted
  • Prior cochlear implantation, in either ear
  • Medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted
  • Medical or psychological conditions that contraindicate general anaesthesia, surgery or participation in the clinical investigation, as determined by the investigator
  • Women who are pregnant
  • Unrealistic expectations on the part of the subject, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices as determined by the Investigator
  • Additional disabilities that may affect the subject's participation or safety during the clinical investigation, as determined by the Investigator
  • Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator
  • Investigator site personnel directly affiliated with this study and/or their immediate families; immediate family is defined as spouse, parent, child, or sibling to the study candidate
  • Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of this investigation
  • Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device (unless Cochlear sponsored and determined by investigator or Sponsor to not impact this investigation)
  • Subjects recruited at a French site who are not affiliated with social security
  • Subjects recruited at a French site who are under legal protection.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:双倍的

武器和干预

参与者组/臂
干预/治疗
实验性的:CI622D

Investigational Medical Device (IMD)

A dexamethasone-eluting Slim Straight electrode

有源比较器:CI622

An approved medical device

A standard Slim Straight electrode

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Difference in the mean impedance between CI622D and CI622
大体时间:6 months post-activation

Mean monopolar impedance measured across the active electrodes of the implant for each participant.

6 months post-activation

次要结果测量

结果测量
措施说明
大体时间
Incidence of Treatment-Emergent Adverse Events of the CI622D and CI622
大体时间:Throughout study (12 months)

Percentage of the number of participants who experience an adverse event for the CI622D group and the CI622 group

Throughout study (12 months)
Difference in the proportion of participants with preservation of low frequency residual hearing with CI622D compared with CI622
大体时间:Pre-implantation to 6 months post activation

The proportion of participants achieving ≤ 30 dB change in the low frequency pure tone average (LFPTA) (250 Hz and 500 Hz). This measure will be applied to the subgroup of participants who have a LFPTA < 80 dB HL at the pre-operative baseline.

Pre-implantation to 6 months post activation
Mean change (within-subject) in word recognition score in the preferred unilateral listening mode in quiet with the CI622D
大体时间:Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Mean change (within-subject) in word recognition score in the preferred bilateral listening mode in quiet with the CI622D
大体时间:Pre-implantation to 6 months post-activation

Change in percent correct word recognition score

Pre-implantation to 6 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred unilateral listening mode in quiet with the CI622D compared with CI622
大体时间:Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in word recognition score in the preferred bilateral listening mode in quiet from pre-implantation to post-activation with CI622D compared with CI622
大体时间:Pre-implantation to 12 months post-activation

Change in percent correct word recognition score

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred unilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
大体时间:Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Difference in mean (within-subject) change in sentence recognition score in noise in the preferred bilateral listening mode from pre-implantation to post-implantation with CI622D compared with CI622
大体时间:Pre-implantation to 12 months post-activation

Change in percent correct sentence recognition score (Matrix test + 10 SNR)

Pre-implantation to 12 months post-activation
Characterization of four-point nested impedances and monopolar impedance of the CI622D and CI622
大体时间:Activation, 12 months post-activation

Group mean impedance measured across the active electrodes for four-point nested impedance and MP1+2 impedance for the CI622D and CI622

Activation, 12 months post-activation
Characterization of mean estimated sound processor battery life for CI622D and CI622
大体时间:12 months post-activation

The estimated sound processor battery life (hours per day) as calculated by the programming software

12 months post-activation
Difference in mean within-subject changes in global score on the Speech, Spatial, and Qualities of Hearing Scale (SSQ12) between CI622D and CI622
大体时间:Pre-implantation to 12 months post-activation

Speech, Spatial, and Qualities of Hearing Scale global score (SSQ-12). Scores range from 0 to 10, where higher scores indicate greater ability (less hearing disability).

Pre-implantation to 12 months post-activation
Difference in mean within-subject changes in global Health Utilities Index III (HUI3) between CI622D and CI622
大体时间:Pre-implantation to 12 months post-activation

Health Utilities Index (HUI 2/3) global score. Scores range from -0.36 to 1.00, where a negative score represents a state "worse than dead" and a top score of 1.00 is "perfect health".

Pre-implantation to 12 months post-activation

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

调查人员

  • 首席研究员:Antje Aschendorff、University Hospital Freiburg

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年6月17日

初级完成 (实际的)

2025年11月5日

研究完成 (实际的)

2026年5月6日

研究注册日期

首次提交

2024年5月16日

首先提交符合 QC 标准的

2024年5月16日

首次发布 (实际的)

2024年5月22日

研究记录更新

最后更新发布 (实际的)

2026年10月8日

上次提交的符合 QC 标准的更新

2026年10月5日

最后验证

2026年10月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅